

Supplementary Table 5. Prescription pattern after discontinuation of 4th OHA

| Prescription pattern | Discontinued agents | No. (%) |
|---|---------------------------------|-----------|
| Discontinuation of quadruple combination of OHAs | | 87 (100) |
| Discontinuation of agent newly added as quadruple combination | | 47 (54.0) |
| | Thiazolidinedione | 23 (26.4) |
| | SGLT2 inhibitor | 12 (13.8) |
| | DPP4 inhibitor | 6 (6.9) |
| | Sulfonylurea or glinide | 3 (3.4) |
| | α -Glucosidase inhibitor | 3 (3.4) |
| Discontinuation of other agent | | 22 (25.3) |
| | Metformin | 7 (8.0) |
| | DPP4 inhibitor | 4 (4.6) |
| | SGLT2 inhibitor | 4 (4.6) |
| | Thiazolidinedione | 3 (3.4) |
| | Sulfonylurea or glinide | 3 (3.4) |
| | α -Glucosidase inhibitor | 1 (1.2) |
| Initiation of injectables (insulin and/or GLP-1 RA) | | 18 (20.1) |

OHA, oral hypoglycemic agent; SGLT2, sodium-glucose cotransporter 2; DPP4, dipeptidyl peptidase 4; GLP-1 RA, glucagon-like peptide-1 receptor agonist.